Response Assessment and Prediction of Progression-Free Survival by (68)Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing (177)Lu-PSMA-617 Radioligand Therapy

At present, little is known about the molecular imaging-based response assessment of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with (177)Lutetium ((177)Lu-PSMA-617 RLT) in metastatic castration-resistant prostate cancer (mCRPC). Our study evaluated the response to RLT us...

Descripción completa

Detalles Bibliográficos
Autores principales: Khreish, Fadi, Wiessner, Mona, Rosar, Florian, Ghazal, Zaidoon, Sabet, Amir, Maus, Stephan, Linxweiler, Johannes, Bartholomä, Mark, Ezziddin, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391209/
https://www.ncbi.nlm.nih.gov/pubmed/34439768
http://dx.doi.org/10.3390/biom11081099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391209/
https://www.ncbi.nlm.nih.gov/pubmed/34439768
http://dx.doi.org/10.3390/biom11081099

Ejemplares similares